A more widespread use of questionnaires and scales such as non-motor symptoms (NMS)-Quest and the non-motor symptoms scale (NMSS) has confirmed that NMS, such as sleeping difficulties and speech problems, are at least as troublesome for Parkinson's disease patients as the major motor symptoms. These NMS can have a profound negative effect on patient quality of life and on the health of the person providing care. This fact is now receiving more attention in clinical practice and measures are being taken to improve the recognition and treatment of NMS, and to provide better support for care-givers. As our knowledge base of NMS expands, we are increasingly finding that some of them, e.g. olfactory deficit and rapid eye movement (REM) sleep behaviour disorder, also occur early in Parkinson's disease, possibly pre-dating a diagnosis based on motor signs alone.
Parkinson's disease (PD) is most commonly recognised as a movement disorder disease. Accordingly, motor symptoms (MS) have been the focus when making diagnoses, prescribing treatment and assessing its effect. Considerable progress has been made in all three areas and effective therapies are now available to improve the quality of life (QoL) of PD patents with early-and late-stage disease. Nevertheless, it is becoming increasingly recognised in clinical practice that non-MS (NMS), such as sleeping difficulties, depression and hallucinations, can be at least as troublesome for patients as the major MS. Furthermore, NMS often have a profound effect on care-giver QoL, an aspect of PD management that has also tended to be overlooked. This article, intended for a readership with a broad interest in PD, reviews these 'neglected' sides of the disease and highlights the value of instruments (questionnaires/scales) for gathering information about NMS and their consequences for patients and carers.
Brief Clinical and Therapeutic Background
The progressive degeneration of the dopaminergic neurons located in the substantia nigra pars compacta depletes the production of the neurotransmitter substance dopamine (DA). 1 When this loss becomes substantial, the ability of the corpus striatum to guide motor behaviour diminishes and the classic symptoms of PD begin to manifest. Four primary MS 2 are recognised. The first is tremor, either in the hand or foot on one side of the body, usually appearing when the muscles are relaxed (hence the term 'resting tremor'). Tremor is the first symptom of PD in the majority of patients. Second is bradykinesia, when patients experience slow or incomplete movements such as walking with short, shuffling steps.
Third is rigidity, stiffness or inflexibility of the muscles that affects activities such as getting up from a sitting position. Rigidity may also cause pain and cramping. Fourth is postural instability, seen as impaired balance and co-ordination. Combined with the symptoms noted above, postural instability increases the risk of falling and leads to freezing, where patients feel stuck to the ground and find it difficult to start walking.
Although degeneration of the DA-releasing neurons is the generally recognised cause of PD, simply replacing DA is not a feasible therapy as the compound does not cross the blood-brain barrier. However, 
Effective Therapy Has Reduced the Major Visible Symptoms
confirm the positive effects of L-dopa/DA agonist therapy on MS (e.g. a large majority of the patient's day spent in 'on' plus almost complete elimination of dyskinesias), the unresolved problem of NMS began to emerge.
Emerging Information of Non-visible Symptoms
In surveys where PD patients were asked to rate the matters they regarded as most important for their QoL, they frequently selected non-motor aspects as being more important than motor problems. 4 For example, they rated pain, sleep problems, cardiovascular problems and urological problems as areas of special concern, and generally felt NMS to be more debilitating than MS. Furthermore, their NMS were not picked up as easily by physicians or neurologists and therefore tended to go untreated. This all points to a need for increased attention to be given to recognising and treating NMS as a means of improving the QoL of people living with PD, as well as for those caring for them.
Common Non-motor Symptoms
The list of NMS now regarded as being capable of impairing the QoL of PD patients is long. Neurodegenerative Diseases Parkinson's Disease The following year, the definitive version of NMSQuest was used to assess 545 PD patients. 8 This study, performed in outpatient clinics at a wide range of centres in several countries in a large population of patients with early-and late-stage disease, confirmed the prevalence of a wide range of NMS. On average, patients reported nine to 12 symptoms and only eight patients (1.6%) declared no NMS at all. Of the nine domains in the NMSQuest, the urinary category scored highest, while depression/anxiety and apathy/attention/memory were the second and third most prevalent categories, respectively. A more detailed analysis showed that the urinary symptoms of nocturnal and urgency were present in 61.9 and 55.8%, respectively, of patients with NMS. Table 2 summarises the frequency and distribution of positive responses classified by NMSQuest domains.
The study also revealed a strong correlation with disease severity.
Hoehn and Yahr (H&Y) staging showed increasing total non-motor symptoms (NMS) scores (NMSQuest-T) with advancing disease (see Figure 1 ). NMSQuest-T values were 8.8±4.9, 12±5.2 and 13±5. Parkinson's and carers of people living with the condition. 9 More than 13,000 members responded and the results clearly showed that most PD carers and their families are not receiving the support or information they need.
Most informal care-givers (91%) were looking after a spouse or partner and 93% lived in the same household. Care-givers under 55 years of age were more likely to be looking after a parent (35%). A high proportion of care-givers of working age either gave up or reduced work in order to care, with the result that more than half (55%) were The greatest worry expressed by the carers was not being able to take care of the PD patient (46%). This was followed by patient neuropsychiatric problems (25%) such as impaired cognition and hallucinations. The most troublesome patient symptoms were motor dysfunction (58%), but NMS such as impaired memory (33%), slowness of mind (30%), sleep disturbance (29%) and psychiatric symptoms (13%) were all regarded as causing carer strain.
Furthermore, many of these symptoms were experienced regularly.
Impaired memory was also a cause of carer worry: 37% of care-givers had to remind patients to take their daily anti-PD medication, for example. Figure 2 summarises the PD patient symptoms that gave carers most cause for concern.
The study concluded that PD imposes a vast strain on care-givers, and it was noted that more than half of those who responded experienced little or no understanding of their situation.
Conclusions
Although the last 30 years have witnessed major advances in the management of the MS of PD, a wide range of NMS such as depression, sleep disorders and hallucinations continue to trouble PD patients and have a negative impact on their QoL. In advanced PD in particular, NMS tend to dominate the clinical situation. Fortunately, NMS are now receiving greater attention. 11 The PDNMG continues to play a prominent role in this work and its NMSS/NMSQuest questionnaires have proved to be valuable instruments for building up the information bank on NMS. They have even indicated that, contrary to common belief, many NMS occur early in PD. Furthermore, some problems, e.g. olfactory deficit, REM sleep behaviour disorder and male erectile dysfunction, may even pre-date a diagnosis of PD based on motor signs. 12 While it is not the intention of this article to discuss therapeutic strategies, we can note that continued progress with continuous dopaminergic stimulation should help decrease or eliminate severe motor complications and thus alleviate one of the biggest concerns for care-givers (see Figure 2 ). In addition, many NMS, e.g. depression,
constipation, nausea, restless legs and urological problems, can be treated by traditional means; however, harder-to-treat symptoms may require new, non-dopaminergic pharmaceutical preparations not yet introduced. This may well go hand-in-hand with the search for treatments that slow neurodegeneration.
Finally, the PD patient and care-giver situations are inevitably intertwined. Recognising care-givers as a group at risk of poor health and thereby providing them with better support will ultimately benefit the QoL of their patients as well. n
